{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:47:19Z","timestamp":1790858839043,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this systematic review was to evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on medical complications, implant failure rates, and health-care-related costs in patients undergoing hip or knee arthroplasty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive search of electronic databases, including PubMed, Embase, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trials Registry Platform (ICTRP), and the UK Clinical Trials Gateway, was conducted and was limited to studies from database inception to March 31, 2025. Inclusion criteria comprised randomized controlled trials or cohort studies involving adults (\u226518 years old) undergoing total joint arthroplasty (TJA) while receiving a GLP-1 RA treatment of any dosage or duration. The risk of bias was assessed using the Cochrane risk-of-bias tool and ROBINS-I (Risk Of Bias In Non-Randomized Studies - of Interventions) assessment. Due to substantial heterogeneity in the study designs, a qualitative synthesis approach was employed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight retrospective studies met the inclusion criteria, encompassing 22,611 GLP-1 RA users and 77,810 controls. The mean patient age ranged from 56 to 64 years. Hospital readmission rates showed the most consistently favorable results among GLP-1 RA users, with 3 studies reporting significant reductions of 29% to 47% during the 90-day postoperative period. Five studies demonstrated that GLP-1 RA use was associated with significant reductions, ranging from 30% to 44%, in periprosthetic joint infection (PJI) rates, whereas 3 studies found no significant differences. Hospital resource utilization favored GLP-1 RA therapy, with several studies demonstrating shorter hospital stays and lower 90-day costs. Medical complications yielded variable results: some studies reported increased vascular and pulmonary events among GLP-1 RA users, whereas others observed reduced sepsis and hypoglycemic events in those patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>GLP-1 RA therapy was associated with reduced hospital readmissions and decreased hospital costs within 90 days postoperatively, although its benefits for PJI prevention showed mixed results, with some studies demonstrating significant reductions in PJI while others showed no difference. No consistent clinical advantages were observed at the 2-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      Therapeutic\n                      <jats:underline>Level III<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.25.00879","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:01:18Z","timestamp":1775066478000},"page":"639-648","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty"],"prefix":"10.2106","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1289-8849","authenticated-orcid":false,"given":"Filippo","family":"Leggieri","sequence":"first","affiliation":[{"name":"Department of Clinical Orthopaedics, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon N.","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sint Maartenskliniek, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente J.","family":"Le\u00f3n Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Instituto de Cirug\u00eda Avanzada de la Rodilla (ICAR), Murcia, Spain"},{"name":"Department of Orthopaedic Surgery and Traumatology, Hospital General Universitario Reina Sof\u00eda, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-2521","authenticated-orcid":false,"given":"Joaquin","family":"Moya-Angeler","sequence":"additional","affiliation":[{"name":"Instituto de Cirug\u00eda Avanzada de la Rodilla (ICAR), Murcia, Spain"},{"name":"Department of Orthopaedic Surgery and Traumatology, Hospital General Universitario Reina Sof\u00eda, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-4208","authenticated-orcid":false,"given":"Mustafa","family":"Akkaya","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics & Traumatology, Y\u00fcksek \u0130htisas University, Ankara, T\u00fcrkiye"},{"name":"Department of Orthopaedics & Traumatology, Ankara G\u00fcven Hospital, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0010-7532","authenticated-orcid":false,"given":"Roberto","family":"Civinini","sequence":"additional","affiliation":[{"name":"Department of Clinical Orthopaedics, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-2042","authenticated-orcid":false,"given":"Matteo","family":"Innocenti","sequence":"additional","affiliation":[{"name":"Department of Clinical Orthopaedics, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"9S1","key":"bib1-20260506","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/j.arth.2025.05.022","article-title":"Effects of Surgeon Volume on Outcomes Following Primary Total Knee Arthroplasty in the Morbidly Obese: An Analysis From the American Joint Replacement Registry","volume":"40","author":"Carender","year":"2025","journal-title":"J Arthroplasty."},{"issue":"5","key":"bib2-20260506","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1302\/0301-620X.107B5.BJJ-2024-0761.R1","article-title":"The safety and efficacy of outpatient total hip arthroplasty in very obese patients","volume":"107-B","author":"Gauthier","year":"2025","journal-title":"Bone Joint J."},{"issue":"7-8","key":"bib3-20260506","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/ans.70170","article-title":"Predictors of Discharge Home Versus Inpatient Rehabilitation Following Total Hip and Knee Arthroplasty-Cohort Study","volume":"95","author":"Martina","year":"2025","journal-title":"ANZ J Surg."},{"issue":"0","key":"bib4-20260506","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.jisako.2025.100861","article-title":"Impact of high body mass index on functionally aligned image-based robotic total knee arthroplasty: Comparable functional outcomes but higher mechanical failures","volume":"12","author":"Koutserimpas","year":"2025","journal-title":"J ISAKOS."},{"issue":"1","key":"bib5-20260506","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ocl.2024.01.003","article-title":"Comorbidities in Total Hip and Knee Arthroplasty Patients: When Is It Okay to Say No?","volume":"56","author":"Akram","year":"2025","journal-title":"Orthop Clin North Am."},{"issue":"10","key":"bib6-20260506","first-page":"e71433","article-title":"Challenges and Complications in Treating Total Knee Arthroplasty in Morbidly Obese Patients","volume":"16","author":"Bocea","year":"2024","journal-title":"Cureus."},{"issue":"8","key":"bib7-20260506","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.arth.2021.02.078","article-title":"Surgeon Decision-Making for Individuals With Obesity When Indicating Total Joint Arthroplasty","volume":"36","author":"Sherman","year":"2021","journal-title":"J Arthroplasty."},{"issue":"16","key":"bib8-20260506","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2106\/JBJS.17.01316","article-title":"Postoperative Blood Glucose Levels Predict Infection After Total Joint Arthroplasty","volume":"100","author":"Kheir","year":"2018","journal-title":"J Bone Joint Surg Am."},{"issue":"5","key":"bib9-20260506","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/11207000221144740","article-title":"Super-obese patients are associated with significant infection burden after total hip arthroplasty","volume":"33","author":"Chen","year":"2023","journal-title":"Hip Int."},{"issue":"4","key":"bib10-20260506","first-page":"e24.00306","article-title":"A Systematic Review and Meta-Analysis of Periprosthetic Joint Infection Rates in Morbidly Obese Patients Undergoing Total Hip Arthroplasty","volume":"9","author":"Rubin","year":"2025","journal-title":"J Am Acad Orthop Surg Glob Res Rev."},{"issue":"4","key":"bib11-20260506","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/17453674.2019.1604940","article-title":"Patient-reported 1-year outcome not affected by body mass index in 3,327 total knee arthroplasty patients","volume":"90","author":"Overgaard","year":"2019","journal-title":"Acta Orthop."},{"key":"bib12-20260506","doi-asserted-by":"crossref","first-page":"101665","DOI":"10.1016\/j.artd.2025.101665","article-title":"Body Mass Index Above 35 Has Increased Risk of Complications but Still Achieves Clinically Meaningful Improvement in Patient-Reported Outcomes After Anterior-Based Total Hip Arthroplasty","volume":"32","author":"Dash","year":"2025","journal-title":"Arthroplast Today."},{"issue":"2","key":"bib13-20260506","doi-asserted-by":"crossref","first-page":"e2461200","DOI":"10.1001\/jamanetworkopen.2024.61200","article-title":"Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement","volume":"8","author":"Xie","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"4","key":"bib14-20260506","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"6","key":"bib15-20260506","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther."},{"issue":"10434","key":"bib16-20260506","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet."},{"issue":"3","key":"bib17-20260506","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications","volume":"40","author":"Moore","year":"2023","journal-title":"Adv Ther."},{"issue":"1","key":"bib18-20260506","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-024-02543-1","article-title":"Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses","volume":"24","author":"Lai","year":"2025","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"bib19-20260506","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MNH.0000000000001066","article-title":"Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond","volume":"34","author":"Faruque","year":"2025","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"2","key":"bib20-20260506","doi-asserted-by":"crossref","first-page":"e175634","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J Clin Invest."},{"issue":"1","key":"bib21-20260506","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.RVW.23.00167","article-title":"Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know","volume":"12","author":"Chan","year":"2024","journal-title":"JBJS Rev."},{"issue":"3","key":"bib22-20260506","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.arth.2024.08.054","article-title":"Body Mass Index Improvement Reduces Total Knee Arthroplasty Complications Among Patients Who Have Extreme, but Not Severe, Obesity","volume":"40","author":"Spezia","year":"2025","journal-title":"J Arthroplasty."},{"issue":"12","key":"bib23-20260506","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.arth.2025.06.083","article-title":"The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis","volume":"40","author":"Chan","year":"2025","journal-title":"J Arthroplasty."},{"issue":"10","key":"bib24-20260506","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12178-025-09978-3","article-title":"The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care","volume":"18","author":"Gatto","year":"2025","journal-title":"Curr Rev Musculoskelet Med."},{"issue":"71","key":"bib25-20260506","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"bib27-20260506","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.joca.2024.02.062","article-title":"SGLT2 inhibitors vs. GLP1 agonists as treatments for osteoarthritis","volume":"32","author":"Jafarzadeh","year":"2024","journal-title":"Osteoarthritis Cartilage."},{"issue":"6","key":"bib28-20260506","doi-asserted-by":"crossref","first-page":"e41243","DOI":"10.1097\/MD.0000000000041243","article-title":"Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study","volume":"104","author":"Lin","year":"2025","journal-title":"Medicine (Baltimore)."},{"issue":"10","key":"bib29-20260506","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","article-title":"The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists","volume":"39","author":"Lavu","year":"2024","journal-title":"J Arthroplasty."},{"issue":"1","key":"bib30-20260506","doi-asserted-by":"crossref","first-page":"23259671241297157","DOI":"10.1177\/23259671241297157","article-title":"The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis","volume":"13","author":"Porto","year":"2025","journal-title":"Orthop J Sports Med."},{"issue":"8","key":"bib31-20260506","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/dom.15636","article-title":"Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists","volume":"26","author":"Klonoff","year":"2024","journal-title":"Diabetes Obes Metab."},{"issue":"9S1","key":"bib32-20260506","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/j.arth.2024.12.008","article-title":"Utilization of Glucagon-Like Peptide-1 Receptor Agonist at the Time of Total Hip Arthroplasty for Patients Who Have Morbid Obesity","volume":"40","author":"Kim","year":"2025","journal-title":"J Arthroplasty."},{"issue":"3","key":"bib33-20260506","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions","volume":"39","author":"Magruder","year":"2024","journal-title":"J Arthroplasty."},{"issue":"11","key":"bib34-20260506","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?","volume":"38","author":"Magruder","year":"2023","journal-title":"J Arthroplasty."},{"issue":"12","key":"bib35-20260506","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty","volume":"39","author":"Buddhiraju","year":"2024","journal-title":"J Arthroplasty."},{"issue":"4","key":"bib36-20260506","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2106\/JBJS.24.00468","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA","volume":"107","author":"Kim","year":"2025","journal-title":"J Bone Joint Surg Am."},{"issue":"6","key":"bib37-20260506","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.arth.2024.10.099","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes","volume":"40","author":"Heo","year":"2025","journal-title":"J Arthroplasty."},{"issue":"7S1","key":"bib38-20260506","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.arth.2025.02.042","article-title":"Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective","volume":"40","author":"Katzman","year":"2025","journal-title":"J Arthroplasty."},{"issue":"8S1","key":"bib39-20260506","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.arth.2025.03.012","article-title":"GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?","volume":"40","author":"Verhey","year":"2025","journal-title":"J Arthroplasty."},{"issue":"6","key":"bib40-20260506","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/EJE-09-0101","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"160","author":"Monami","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"bib41-20260506","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA."},{"issue":"1","key":"bib42-20260506","doi-asserted-by":"crossref","first-page":"2478488","DOI":"10.1080\/0886022X.2025.2478488","article-title":"Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization","volume":"47","author":"Yao","year":"2025","journal-title":"Ren Fail."},{"issue":"40","key":"bib43-20260506","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"8","key":"bib44-20260506","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4239\/wjd.v14.i8.1280","article-title":"Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients","volume":"14","author":"Huang","year":"2023","journal-title":"World J Diabetes."},{"key":"bib45-20260506","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","article-title":"Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing","volume":"208","author":"Roan","year":"2017","journal-title":"J Surg Res."},{"issue":"1","key":"bib46-20260506","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12967-017-1145-4","article-title":"Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing","volume":"15","author":"Seo","year":"2017","journal-title":"J Transl Med."}],"container-title":["Journal of Bone and Joint Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.25.00879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:54:15Z","timestamp":1787752455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.25.00879"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.25.00879","relation":{},"ISSN":["0021-9355","1535-1386"],"issn-type":[{"value":"0021-9355","type":"print"},{"value":"1535-1386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}